NCT02564354View on ClinicalTrials.gov

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Cystic Fibrosis
Interventions
DRUG

QR-010

Single-stranded RNA antisense oligonucleotide in isoosmolar solution

Trial Locations (5)

3000

U.Z. Leuven, Leuven

35233

University of Alabama at Birmingham, Birmingham

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

75743

Hopital Necker-Enfants Malades, Paris

80206

National Jewish Health, Denver

Sponsors

Lead Sponsor

ProQR Therapeutics
All Listed Sponsors
collaborator

European Commission

OTHER

lead

ProQR Therapeutics

INDUSTRY

NCT02564354 - Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation | Biotech Hunter | Biotech Hunter